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This paper analyses funding patterns and their evolution in two medical research topics: breast cancer and ovarian cancer, 
taking into account cross-agency and cross-national co-funding. A bibliometric analysis of 355,463 papers from PubMed 
(273,526 on breast cancer and 81,937 on ovarian cancer) brought back 91 funding agencies involved in breast cancer and 65 in 
ovarian cancer. Additionally, the article examined the evolution of Medical Subject Headings (MESH) funded by agencies. An 
analysis of patterns in funding, co-funding, MESH, and their evolution, was carried out using Social Network Analysis (SNA) 
methodology. The results show the importance of the National Cancer Institute (NCI) in both breast and ovarian cancer. The 
NCI achieves its policy goals by co-funding its programmes with both national and cross-national agencies. Moreover, the 
MESH that agencies co-funded in the two years studied coincided; however, it must be said that the number of agencies which 
participated in research funding also increased. 
Keywords: co-funding research; Medical Subject Headings (MESH); cancer research; social network analysis. 
1. Introduction 
There are a number of open questions to be analysed regarding the role of funding agencies in the 
production of scientific activity. The first question concerns the role of research funding agencies in the 
selection and prioritisation of research topics deserving further funding. The second question concerns 
how funding agencies accomplish their policy objectives in tandem with other research funders. Although 
separate funding agencies wish to work together, obstacles occur as a result of agency preferences, 
national and organisational boundaries, and the nature of the funding instruments used. A third question 
therefore centres on the obstacles encountered by research funding agencies when funding scientific 
research, given the different cultures, objectives, and instruments found in cross-funding recipients.  
 
This paper helps to address some of these questions by using funding acknowledgements from a national 
medical funding database. Although there is a growing availability of this data, there is still a relative lack 
of empirical papers which utilise this information [Vanderelst and Speybroeck (2013); Zhou and Tian 
(2014); Tahmooresnejad et al. (2014)]. Yet, thanks to this data we are able to investigate a number of 
questions, including the co-funding patterns of research agencies, and how funding differs according to 
topics and domains. Finally, this novel source of information enables us to dig deeper into the role of 
capstone funding agencies in creating a larger ecology of funders and principal investigators.  
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We investigated these questions and this data using two medical research topics selected from the 
PubMed database. The paper is organised as follows. Section 2 provides a short literature review of some 
of the key questions underlying the production of scientific knowledge through research funding and 
funding agencies. Section 3 provides a methodological review of specific methods used to investigate 
these questions. Section 4 details the data, and its cleaning and extraction. Section 5 shows the results of 
social network analysis and co-word analysis of the database. The paper concludes in section 6 with 
recommendations and topics for future research.  
 
2. Literature Review 
The processes of selecting, prioritising and funding specific areas in science are complex and varied. 
There are no palimpsests to be read which describe the key issues to be addressed through science, or the 
needs of society which might be met through scientific funding. Any effort to select topics for further 
funding must meet a balance of external and internal criteria [Weinberg (1963)]. External criteria include 
the perceived need and value of research in society. Internal criteria involve maintaining a pipeline of 
viable research, as well as a stable of scientific talent across the entirety of the life cycle.  
 
Access to funding is a matter of governance, addressed like many other societal questions from the 
viewpoint of the use of scarce resources [Cunningham (2007)]. Direct societal and citizen input into 
scientific funding occurs through science advisory councils [Brickman and Rip (1979)]. Nonetheless, 
even this mechanism has changed over time given the general availability of funding and changing public 
attitudes towards public funding for science and technology. The military is a common sponsor of science 
in a broad range of disciplines. The specific purpose of military funding is to develop weapons, or  further 
foreign policy objectives [Doel (2003)]. The extent to which science is funded by the state as a public 
good is part of a larger political agenda waged between larger, self-sufficient corporations and smaller 
firms with limited resources [Lassman (2005)]. A new economics of science questions the allocative 
efficiency of funding agencies as a means towards providing a broader, conceptual framework for 
analysing science and its funding [Dasgupta and David (1994)].  
 
Science is increasingly a polycentric activity, funded by a variety of different actors for a variety of 
different purposes. In the developed world, national governments and their respective agencies are not 
necessarily the dominant source for funding science and technology. This has arisen as a result of a 
decline in national funding in the wake of the Cold War, as well as an increase in private-sector funding. 
The consequence of this is that public science is produced from an amalgam of different sources, 
providing funding with different purposes, different terms, and differing conditions.  
 
Transdisciplinary research thrives in the boundaries between different organisations, as well as in the 
formulation and translation of research to meet the varied needs of society [Nowotny et al. (2003)]. 
Despite the opportunities that are created by new modes of knowledge production, care is still needed in 
selecting from a diverse portfolio of potential research topics [Stirling (2007)]. Explicit attention is 
necessary in enhancing overall participation and deliberation concerning the selection of research. An 
amalgamation of funding can lead to a lack of inter-agency coordination, and certainly introduces new 
modes of potential system failure [Negro et al. (2012]. Overweening failure, to which even centralised 
agencies are subject, is a premature lock-in into undesirable or inefficient forms of technology [Cowan 
(1991)]. This problem is exacerbated when research funding is scarce, and scientific choice is thereby 
restricted.  
  
Funding agencies face obstacles in the selection of research projects. These obstacles emerge out of hard 
and soft institutional rules. Epistemic boundaries on funding occur given the specific objectives of the 
funding agency, which may limit the kinds of science it is funding. There are also agency problems – the 
agency may find it difficult to effectively evaluate certain kinds of knowledge with which it is not 
familiar. National or geographical limits on funding can also occur given the specific mission of the 
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agency. Other obstacles occur because of differing incentives between the funding agency and the 
respective scientific organisations which receive funding. These kinds of obstacles exist between funding 
agencies and funded organisations, but they also manifest themselves as challenges on which funding 
agencies need to work together towards common interests.  
 
The issue of funding obstacles has been addressed in part by the Dutch school of geography, which 
addresses and generalises the concept of proximity. Proximity entails geographical factors, but also 
includes epistemic and institutional factors as well [Cunningham and Werker (2012)]. These funding 
obstacles are partly considered within extensive literature on technology transfer. Literature highlights the 
many contingent factors under which funding is successful, and technological knowledge is then 
transferred [Bozeman (2000)]. Nonetheless, and despite these hurdles, the importance of publically 
funded science for the production of new technology is well documented [Narin et al. (1997)].  
 
Despite renewed calls to set forth an agenda for research into scientific policy [Sutherland et al. (2012)], 
the three questions set forth here have received relatively little coherent attention in literature. There is an 
even greater gap when it comes to systematic and empirical evidence for how scientific networks are 
shaped by their funding. An exception is Lewison (1998) whose investigations centred on the diversity of 
research funding associated with research teams in medical research. Given this gap in the literature, an 
exploratory and empirical analysis of how epistemic networks are shaped by funding agencies, and how 
funding agencies find (or fail to find) common cause with other agencies, is of empirical and theoretical 
interest.  
 
3. Methodology  
Bibliometric and scientometric analysis are common in the representation of science maps in literature 
reviews, including medical literature reviews [Zhang et al. (2013); Ramlogan and Consoli (2014)]. 
Measures like co-authorship and co-word analyses are frequently used to analyse data. Moreover, the 
Social Network Analysis (SNA) methodology is also used to find out who the main research actors are, 
whether people, institutions, or countries. The technique is also used to reveal cooperation between 
actors, and keyword co-occurrence. This constellation of metrics is very helpful in understanding how 
knowledge evolves in a specific field. 
 
The measures from Social Network Analysis usually employed in literature reviews are centrality, 
including degree centrality, closeness and betweenness. Moreover, statistical analyses, such as cluster 
detection and multidimensional scaling, are also applied to group together words, authors, and 
institutions. Degree centrality, in the case of variables organised in 1-mode matrix, represents the most 
important nodes in the network, that is, nodes that have the largest number of connections (links) with 
other nodes. Closeness defines the average distance between one node and other nodes [Borgatti et al. 
(2013)], and betweenness indicates whether a node is frequently located on paths between other nodes 
[Kolaczyk (2009)]. An additional measure for networks, which is useful in a dense network, is clique 
detection. A clique is a sub-network with three nodes or more [de Nooy et al. (2012] in which all actors 
are directly connected to all others [Hanneman and Riddle (2011)].  
 
Bibliometric and scientometric analyses and SNA are often complemented with the visualisation of 
networks, a tool which helps to reveal key information about the network [Ozcan and Islam (2013); Feng 
et al. (2015)]. Tools for visualising networks have been developed over the last few years, both in 
commercial and free formats [van Eck and Waltman (2010); Cobo et al. (2011); Light et al. (2014)]. 
These tools, like VOSViewer [van Eck and Waltman (2010)] and Gephi [Bastian et al. (2009)], also allow 
researchers to apply measures and models to analyse nodes and links, including centrality measures and 
clustering. 
 
Collaborative network analysis has been employed to study relationships between authors and 
organisations in many different disciplines [Kumar and Jan (2013); Qiu et al. (2014)]. In the case of 
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health, there are studies in which data about collaboration comes from academic papers [Catalá-López et 
al. (2014); Andersen et al. (2015)], whilst in other studies these come from website inter-linkages 
[Barreto Lang et al. (2013)]. 
 
Co-words and co-keyword analysis are also measures used in papers where bibliometric and 
scientometric analyses are applied as the main methodology [Neff and Corley (2009); Yu et al. (2013)]. 
The analysis of words in the titles and abstracts of papers is described as a useful instrument by 
Leydesdorff and Zaal (1988), because authors are precise in their selection of words. In the case of 
keywords, authors have also stressed the use of co-word analysis as an option to display and map the 
literature in a particular scientific field [Zhang et al. (2012); Ravikumar et al. (2015)]. 
 
In the field of medical research, the use of MESH appears when the PubMed database is used as the 
source of papers that researchers use to obtain data. For example, Siqueiros-García et al. (2014) utilised 
network analysis to evaluate differences in the number of nodes (MESH) and edges between periods. 
They used 1-mode networks and calculated centrality measures, average shortest path length and number 
of neighbours. With these measures, they observed which MESH gained in connectivity with others over 
time. However, other authors like Zhang et al. (2012) preferred to make queries in the Web of Science 
instead of in more specialised databases, such as PubMed. 
 
The use of information in acknowledgments is less common than the use of citations. As a consequence, 
there is a lack of papers examining funding agencies which appear in acknowledgements [Vanderelst and 
Speybroeck (2013); Zhou and Tian (2014); Tahmooresnejad et al. (2015)]. This is the reason behind this 
paper as it aims to cover the gap in the analysis of funding agencies through acknowledgements in papers. 
To achieve this, our efforts centred on finding the answers to three questions: 
Q1: How did co-funding patterns differ between 2003 and 2013? 
Q2: How do funding patterns differ depending on NCI involvement and cross-national co-funding? 
Q3: How do funding patterns differ depending on the MESH that agencies fund? 
 
4. Data  
The PubMed database enabled us to obtain all the papers available in the two topics under study: ovarian 
cancer and breast cancer. These were analysed separately in order to find similarities and differences. The 
queries used are shown below:  
 
a) Topic=("breast neoplasms"[MeSH] OR ("breast"[All Fields] AND "neoplasms"[All Fields]) OR 
"breast neoplasms"[All Fields] OR ("breast"[All Fields] AND "cancer"[All Fields]) OR "breast 
cancer"[All Fields]) AND ("2009/04/21"[PDat] : "2014/04/19"[PDat] AND cancer[sb]) 
 
b) Topic=("ovarian neoplasms"[MeSH] OR ("ovarian"[All Fields] AND "neoplasms"[All Fields]) OR 
"ovarian neoplasms"[All Fields] OR ("ovarian"[All Fields] AND "cancer"[All Fields]) OR "ovarian 
cancer"[All Fields]) AND cancer[sb] 
 
Data on funding agencies was obtained from the acknowledgments that appeared in the papers. To obtain 
the names of the agencies appearing in these acknowledgements, the numbers of grants were cleaned 
using the software VantagePoint [Porter and Cunningham (2005)]. This software was also used to clean 
the MESH and obtain 1-mode matrixes for agency co-funding and MESH co-occurrence, and 2-mode 
networks for agency-by-MESH co-occurrence. Ucinet6 software [Suominen (2014); Swar and Khan 
(2014); Kim et al. (2014)] was used for the Social Network Analysis.  
 
Table 1 shows a summary of the records used in our analysis. Although information about funding 
depends on the period analysed (Figure 1), the database as a whole estimated that 18% of papers included 
information about funding agencies (Table 1). Network visualisation was carried out using Gephi 
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[Bastian et al. (2009)] and VOSViewer software [van Eck and Waltman (2010)], which was also utilised 
for clustering the MESH. A summary of the steps followed is shown below: 
 
1. Queries made in PubMed. 
2. Two files were downloaded in text format, one for each topic, imported in VantagePoint 
software. 
3. The information in acknowledgements was cleaned to extract research agencies using 
VantagePoint software. 
4. A sub-data set was created for the years spanning from 2003 to 2013 for each topic using 
VantagePoint software. 
5. For each year and topic, the agencies and MESH were listed to obtain relevant records and 
order the relevant records by importance, using VantagePoint software. 
6. The matrices for each year and topic were developed, creating agency-by-agency, MESH-
by-agency and MESH-by-MESH matrices, using VantagePoint software. 
7. Centrality measures were calculated using Ucinet6.  
8. Networks of co-funding agencies were visualised using Gephi.  
9. The MESH were clustered and networks were visualised using VOSViewer.  
 
 
Table 1. Summary of data used in the analysis 
 Med1 (ovarian cancer) Med 2 (breast cancer) 
Total records 81,937 273,526 
Records that included funding details 14,560 (17.77%) 48,948 (17.9%) 
Number of funding agencies 65 91 
Funding agencies that coincide 63 63 
Funding agencies that do not coincide 28 2 










Fig. 1. Percentage of papers which give funding information by year. Source: own source from cleaned PubMed data 
5. Results 
Once the data had been cleaned with VantagePoint software, the first results obtained showed that the 
majority of funding agencies for the two topics were located in the United States (about 80%), followed 
by the United Kingdom, Canada, Austria, Italy, Ireland, and in other European countries represented by 
the European Research Council. 
 
Figures 2 to 5 show that the majority of the agencies funded breast cancer research first and then ovarian 
cancer research. Moreover, the number of agencies that funded research into both topics increased during 
the ten year period. 
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Table 2 features a summary of the most important results obtained from the Social Network Analysis. It 
is obvious that the National Cancer Institute (NCI) is the most important funding agency for the two 
medical topics and the two periods analysed. Degree centrality also shows the importance of the National 
Centre for Research Resources (NCRR) for both topics, while the National Institute of General Medical 
Sciences (NIGMS) was present in ovarian cancer and the Public Health Service (PHS) emerged in breast 
cancer. The betweenness centrality of the NCRR, NIGMS and NIMH is also important. These agencies 
are central nodes for those accessing the NCI. This is also the case of the WHI and NCPDCID (Figure 2). 
Therefore, in figures 2 to 5 we can see that the main differences between 2003 and 2013 depended on: 
a) The existence of cross-agency co-funding, and the appearance of the NCI as a co-funding 
agency,  
b) The existence of cross-national co-funding, and  
c) The number of participants involved in co-funding. 
 
 
Table 2. Summary of Social Network Analysis. Centrality measures 
 Med1 Y2003 Med1 Y2013 Med2 Y2003 Med2 Y2013 
Network density 21.57% 18.5% 16.9% 23.6% 
































NCI: National Cancer Institute; NCRR: National Center for Research Resources; NIGMS: National Institute of General Medical 
Sciences; PHS: Public Health Service; NIMH: National Institute of Mental Health; Source: own source from cleaned PubMed data 
 
 
5.1. Co-funded research into ovarian cancer 
 
Figure 2 and Figure 3 represent the evolution in co-funded research into ovarian cancer between 2003 and 
2013. It is evident that the number of agencies that funded research in this topic increased over the period, 
and the number of links between agencies expanded. In order to better analyse the number of links and 
their patterns, cliques were calculated for every network. Each participant in the clique had ties with the 
















Fig. 2. Co-funded research into ovarian cancer in 2003. Visualisation using Gephi software. Nodes: 21; links: 33. Source: own 
















Fig.3. Co-funded research into ovarian cancer in 2013. Visualisation using Gephi software. Nodes: 42; links: 144. Source: own 
source from cleaned PubMed data 
 
 
Next, we calculated the cliques where there were more than three funding organisations. We found 10 
cliques for ovarian cancer in 2003 and 38 cliques in 2013: 
 
1. NCI	 NIH	 HHS/United	 States;	 NICHD	 NIH	 HHS/United	 States:	 NCRR	 NIH	 HHS/United	 States;	 NIGMS	 NIH	
HHS/United	States.	
2. NCI	 NIH	 HHS/United	 States;	 NCRR	 NIH	 HHS/United	 States;	 NIGMS	 NIH	 HHS/United	 States;	 NHLBI	 NIH	
HHS/United	States.	
3. NCI	 NIH	 HHS/United	 States;	 NCRR	 NIH	 HHS/United	 States;	 NIGMS	 NIH	 HHS/United	 States;	 NHGRI	 NIH	
HHS/United	States.	
4. NCI	NIH	HHS/United	States;	NIGMS	NIH	HHS/United	States;	NIAID	NIH	HHS/United	States.	
5. NCI	 NIH	 HHS/United	 States;	 NICHD	 NIH	 HHS/United	 States;	 NIGMS	 NIH	 HHS/United	 States;	 NIDDK	 NIH	
HHS/United	States.	
6. NCI	 NIH	 HHS/United	 States;	 NIGMS	 NIH	 HHS/United	 States;	 NIDDK	 NIH	 HHS/United	 States;	 NHLBI	 NIH	
HHS/United	States.	
7. NCI	NIH	HHS/United	States;	NIGMS	NIH	HHS/United	States;	NIEHS	NIH	HHS/United	States.	






We use the term clique in the strictest sense of the word, which means that each participant in the clique 
has ties with the rest of nodes which form the clique. When comparing the year 2003 with 2013 we can 
see that agencies that were not directly connected to the NCI in the network in 2003 do not appear in any 
clique (WHI and NCPDCID). However, while some agencies were not connected directly to the NCI in 
2013, they do appear in cliques (NINR, British Heart Foundation). In addition, in 2003 the NCI was 
involved in every clique, while in 2013 it only appeared in 35 cliques (92% of cliques). Moreover, in 
2003 all the cliques were formed by United States agencies, while in 2013 we observe that 11 cliques 
incorporated cross-national co-funding (28.9% of cliques). The nations involved in these 11 cliques were 
United States, Canada and United Kingdom (these three nations appeared in four cliques, United States 
and United Kingdom in six cliques, and United States and Canada in one clique). We only included the 
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• C4:	 NCI	 NIH	 HHS/United	 States;	 Canadian	 Institutes	 of	 Health	 Research/Canada;	 Cancer	 Research	
UK/United	 Kingdom;	 NIGMS	 NIH	 HHS/United	 States;	 NCRR	 NIH	 HHS/United	 States;	 Medical	 Research	
Council/United	Kingdom;	PHS	HHS/United	States;	Wellcome	Trust/United	Kingdom.	
• C5:	 NCI	 NIH	 HHS/United	 States;	 Canadian	 Institutes	 of	 Health	 Research/Canada;	 Cancer	 Research	
UK/United	 Kingdom;	 NIGMS	 NIH	 HHS/United	 States;	 NCRR	 NIH	 HHS/United	 States;	 PHS	 HHS/United	
States;	NIEHS	NIH	HHS/United	States.	










• C35:	 NCI	 NIH	 HHS/United	 States;	 Cancer	 Research	 UK/United	 Kingdom;	 NCRR	 NIH	 HHS/United	 States;	
NIEHS	NIH	HHS/United	States;	CCR	NIH	HHS/United	States.	
• C36:	 Canadian	 Institutes	 of	 Health	 Research/Canada;	 NICHD	 NIH	 HHS/United	 States;	 NIGMS	 NIH	
HHS/United	 States;	 NCRR	 NIH	 HHS/United	 States;	 NIEHS	 NIH	 HHS/United	 States;	 British	 Heart	
Foundation/United	Kingdom.	





For co-funding in ovarian cancer, we can conclude that: 
 
a) In 2003, the NCI was involved in every clique, while in 2013 it appeared in 35 cliques (92% of 
all cliques). 
b) In 2003, all of the cliques were formed by United States agencies, while in 2013 we observe that 
11 cliques incorporated cross-national co-funding (28.9% of cliques). 
c) The nations involved in these 11 cliques were United States, Canada and United Kingdom. 
These three nations appeared in four cliques, United States and United Kingdom in six cliques, 
and United States and Canada in one clique. 
 
5.2. Co-funded research into ovarian cancer 
 
Figure 4 and Figure 5 represent the evolution in co-funded research into breast cancer between 2003 and 
2013. It is clear that the number of agencies that funded research into this topic increased over the period, 
and that the number of links between agencies grew, as the cliques illustrate. It is important to point out 
that the agencies that were only related to the NCI in 2003 appeared to be connected to more agencies in 



















Fig.4. Co-funded research into breast cancer in 2003. Visualisation using Gephi software. Nodes: 38; links: 95. Source: own source 


















Fig.5. Co-funded research into breast cancer in 2013. Visualisation using Gephi software. Nodes: 51; links: 278. Source: own source 




In terms of breast cancer, there were 32 cliques which featured more than three funding organisations in 






























































A comparison of 2003 and 2013 reveals the importance of the NCI, which appeared in 31 cliques in 2003 
and in 67 in 2013. Moreover, in 2003 all the cliques were formed by United States agencies, while in 
2013 we can see that 25 cliques incorporated cross-national co-funding (36% of cliques). The nations 
involved in these 25 cliques were United States, Canada, United Kingdom, Austria and the European 
Research Council (United States and Canada appeared in 12 cliques; United States and United Kingdom 
in seven cliques; United States, United Kingdom and Canada in four cliques; United States and Austria in 
one clique; and United States, United Kingdom and the European Research Council in one clique). We 
only included the cliques where cross-national funding appeared. The complete results about cliques can 






































































For co-funding in breast cancer, we can conclude that: 
 
a) The NCI is important, as it appeared in 31 cliques in 2003 and in 67 in 2013. 
b) In 2003, all of the cliques were formed by United States agencies, while in 2013 we observe that 
25 cliques incorporated cross-national co-funding (36% of cliques). 
c) The nations involved in these 25 cliques were United States, Canada, United Kingdom, Austria 
and the European Research Council. United States and Canada appeared in 12 cliques; United 
States and United Kingdom in seven cliques; United States, United Kingdom and Canada in four 
cliques; United States and Austria in one clique; United States, United Kingdom and the 
European Research Council in one clique. 
 
 
Table 3 summarises the main results for both types of cancer, indicating that the NCI is the most 
important agency in both cases; this has also been demonstrated with cliques. An important difference 
found between ovarian and breast cancer research is that in ovarian research cross-national co-funding 
between the United States and United Kingdom prevailed (6 cliques), while in breast research the 
dominant linkage occurred between United States and Canada (12 cliques). 
 
 
Table 3. Summary of co-funded research patterns 
 Med1 Y2003 Med1 Y2013 Med2 Y2003 Med2 Y2013 
 12 
Non co-funding agencies (isolated in network) 3 2 4 2 
Cross-agency with NCI (number of cliques) 10/10 35/38 31/32 67/70 
Cross-agency without NCI (number of cliques) 0 3 1 3 









European Research Council 
Source: own source from cleaned PubMed data 
 
 
3.3. Evolution in the funding of MESH  
 
This section analyses the most important medical subject headings (MESH) funded and the evolution of 
these terms in the two medical research fields under study. It then explores the headings which were most 
significant depending on the respective funding agency. In all the cases, only the terms with 50 records or 
more were selected. 
 
The MESH that appeared in papers in which acknowledgments included agencies supporting research are 
shown in Tables 3 and 4. As there were too many terms, the tables only included the first 30 headings (by 
order of importance). In Table 3, the MESH for ovarian cancer research indicate that the five most 
common terms were the same for the two years analysed: “humans”, “female”, “middle-aged”, “adult”, 
and “aged”. However, if we compare 2013 to 2003, we can see that terms like “cell line, tumour”, “gene 
expression regulation”, and “cell proliferation” increased in importance over the period. However, terms 
like “male” and “immunohistochemistry” were less important in 2013 than in 2003. Table 4 shows that 
the five most important terms in breast cancer did not change between 2003 and 2013. These terms were 
“humans”, “female”, “middle-aged”, “adult” and “aged”. A comparison of the two reference years 
showed that the terms which became more popular in the list over the period were “cell line, tumour”, 




Table 3. Ranking of MESH for ovarian research in 2003 and 2013 
 
Order Records med1 
Y2003 
MESH Order Records 
med1 Y2013 
MESH  
1 2508 Humans 1 2541 Humans 
2 2383 Female 2 2396 Female 
3 902 Middle-Aged 3 960 Middle-Aged 
4 832 Adult 4 817 Adult 
5 655 Aged 5 714 Aged 
19 148 Cell Line, Tumour 6 501 Cell Line, Tumour 
6 356 Animals 7 430 Animals 
10 230 Prognosis 8 327 Prognosis 
14 188 Aged, 80 and over 9 318 Aged, 80 and over 
7 286 Neoplasm Staging 10 317 Neoplasm Staging 
13 199 Mice 11 289 Mice 
8 280 Male 12 243 Male 
16 163 Retrospective Studies 13 232 Retrospective Studies 
   14 223 Young Adult 
11 220 Treatment Outcome 15 203 Treatment Outcome 
28 104 Gene Expression 
Regulation, Neoplastic 
16 189 Gene Expression 
Regulation, Neoplastic 
 13 
17 154 Risk Factors 17 184 Risk Factors 
12 208 Immunohistochemistry 18 149 Immunohistochemistry 
15 166 Adolescent 19 145 Adolescent 
37 83 Disease-Free Survival 20 140 Disease-Free Survival 
44 71 Follow-Up Studies 21 137 Follow-Up Studies 
26 112 Mutation 22 135 Mutation 
42 72 Case-Control Studies 23 125 Case-Control Studies 
31 99 Survival Rate 24 125 Survival Rate 
   25 123 Cell Proliferation/drug 
effects 
   26 118 Neoplasm Grading 
51 66 Mice, Nude 27 104 Mice, Nude 
30 100 Drug Resistance, 
Neoplasm 
28 102 Drug Resistance, Neoplasm 
830 3 Cell Proliferation 29 101 Cell Proliferation 
   30 101 Kaplan-Meier Estimate 
Source: own source from cleaned PubMed data 
 
 











1 8810 Humans 1 8059 Humans 
2 7141 Female 2 7083 Female 
3 3375 Middle-aged 3 3033 Middle-aged 
4 2687 Adult 4 2461 Adult 
5 2463 Aged 5 2270 Aged 
20 456 Cell Line, Tumour 6 1472 Cell Line, Tumour 
7 1213 Animals 7 1430 Animals 
6 1230 Male 8 1053 Male 
12 658 Mice 9 967 Mice 
9 833 Aged, 80 and over 10 935 Aged, 80 and over 
11 728 Prognosis 11 876 Prognosis 
10 814 Risk Factors 12 655 Risk Factors 
14 552 Neoplasm Staging 13 640 Neoplasm Staging 
13 598 Treatment Outcome 14 633 Treatment Outcome 
19 478 Retrospective Studies 15 562 Retrospective Studies 
23 362 Gene Expression Regulation, 
Neoplastic 




3 Young Adult 17 515 Young Adult 
   18 504 MCF-7 Cells 
24 347 Follow-Up Studies 19 495 Follow-Up Studies 
   20 388 Cell Proliferation/drug effects 
198
6 
5 Cell Proliferation 21 357 Cell Proliferation 
15 550 Time Factors 22 353 Time Factors 
16 538 Immunohistochemistry 23 342 Immunohistochemistry 
22 373 Lymphatic Metastasis 24 341 Lymphatic Metastasis 
 14 
165 81 Receptor, erbB-2/metabolism 25 338 Receptor, erbB-2/metabolism 
72 172 Receptors, Estrogen/metabolism 26 333 Receptors, Estrogen/metabolism 
50 236 Neoplasm Invasiveness 27 328 Neoplasm Invasiveness 
46 253 Disease-Free Survival 28 327 Disease-Free Survival 
29 312 Prospective Studies 29 311 Prospective Studies 
28 316 Case-Control Studies 30 309 Case-Control Studies 
 
Source: own source from cleaned PubMed data 
 
 
Networks of co-occurrence in MESH are presented in Figures 6 to 9, where differences in networks 
represent an evolution in the position of the nodes and their linkages. Visualisation was carried out using 
VOSViewer, which allowed us to cluster words. Figure 6 shows the co-MESH for 2003 in ovarian 
cancer, while Figure 7 represents 2013. The VOSViewer software grouped the 71 terms from 2003 into 
five clusters, and the 81 terms for 2013 into four clusters. For example, the first cluster included terms 
like “humans”, “female” and “tumour cell, cultured” in both years, while the second cluster grouped 
terms like “middle-aged”, “adult”, “aged” and “prognosis”. In breast cancer, the software divided the 281 
terms for 2003 into six clusters, and the 244 terms for 2013 into four clusters. It also clustered terms like 
“humans” and “female” in the two years, but not with the same words as in ovarian cancer.  
 
Moreover, in 2003, eigenvector centrality for ovarian cancer was higher for the MESH “humans”, 
“female”, “middle-aged”, “adult” and “male”. These terms also showed high closeness and betweenness. 
In 2013, the eigenvector centrality, closeness, and betweenness were highest for “humans”, “female”, 
“middle-aged” and “animals”. In the case of breast cancer, the highest values were for “humans” and 
“female”, both for 2003 and 2013. In order to better detect the importance of the MESH, Tables 5 to 8 
show which of them were funded by the most important research agencies. We tried to ascertain whether 




























Figure 6. Co-occurrence in MESH for ovarian cancer research in 2003. Visualisation using VOSViewer software. Nodes: 71; links: 


























Figure 7. Co-occurrence in MESH for ovarian cancer research in 2013. Visualisation using VOSViewer software. Nodes: 81; links: 



























Figure 8. Co-occurrence in MESH for breast cancer research in 2003. Visualisation using VOSViewer software. Nodes: 281; links: 





























Figure 9. Co-occurrence in MESH for breast cancer research in 2013. Visualisation using VOSViewer software. Nodes: 244; links: 




The evolution of agency-funded MESH is presented in Tables 5 to 8. In ovarian cancer research, the two 
most important MESH in 2003 were still the most important terms in 2013. However, the increasing 
importance of cell line and genetics is clear in 2013 (Table 6).  
 
The calculation of degree centrality in the affiliation matrix for MESH showed that those ranked highest 
in 2003 were “female”, “humans”, “animals”, “tumour cells, cultured”, “male” and “middle-aged”. In 
2013, the highest centrality was for the terms “human”, females”, “animals”, “middle-aged” and “cell 
line, tumour”. Therefore, the study of cell lines acquired greater significance during the decade. In all 
cases, centrality was related to terms for which there was a higher coincidence in agencies funding them, 
because the matrices used to obtain affiliation matrices were 2-mode networks. The degree in the 
affiliation matrix for funding agencies indicates the agencies coinciding in the MESH they funded. In 
ovarian cancer research, these agencies were NCI, NCIHD, NCRR, and NIGMS in 2003, whilst in 2013, 
the agencies with the highest degree centrality were NCI, the Canadian Institutes of Health Research, the 
NICHS, Cancer Research UK, NIGMS and NCRR. Therefore, the most important agencies funding 
research in this field also funded other similar medical subject headings. This concurrence may explain 
the fact that these agencies appear together in co-funding cliques. 
 
For breast research (Tables 7 and 8), the evolution in the MESH financed by agencies shows that 
“humans” and “female” were also the terms which appeared most frequently in papers. In this case, the 
increasing importance of terms related to cell line and genetics also became patent.  
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When centrality measures were obtained, the terms with the highest degree centrality in 2003 were 
“humans”, “female”, “adult”, “middle-aged” and “aged”. In 2013, the terms with the highest degree were 
“humans”, “female”, “middle-aged”, “adult”, “cell line, tumour” and “aged”. As is the case of ovarian 
research, the prevalence of the term “cell line” grew in importance. Moreover, the degree centrality in 
agencies indicated which ones coincided in funding research in these areas. In 2003, agencies like the 
NCI, NIDDK, NHLBI, NIGMS, NCRR, and NIEHS coincided in the medical subject headings they 
funded. In 2013, concurrence occurred in the agencies NCI, NCRR, NIGMS, Canadian Institutes of 
Health Research, PHS and Cancer Research UK. These agencies also appeared together in the previously 
calculated cliques. 
 
On the other hand, when comparing centrality measures in MESH-by-MESH networks represented in 
Figures 6 to 9 whose results appear in Tables 5 to 8, we can conclude that the most important terms in 
word co-occurrence were also those where agencies coincided most in funding. 
 
Finally, we used VantagePoint software to obtain the MESH that were used in funded research papers in 
2012 and those which started to be used in 2013. In the case of ovarian cancer, we found that terms like 
“cell division”, “neoplasm proteins/genetics”, “BRCA2 protein”, “tumour suppressor proteins”, “BRCA1 
protein” and “receptor, erbB-2/immunology” were not included after 2012. For breast cancer, we detected 
this situation in terms like “tumour cell, cultured/drug effects”, BRCA2 Protein”, “Proto-Oncogen 
Proteins c-akt”, “Cell cycle proteins”, “aromatase proteins” and “carcinogens”. Headings first used in 
2013 in ovarian cancer showed “adenocarcinoma, clear cell/ pathology”, “adenocarcinoma, mucinous/ 
pathology”, “cytodiagnosis”, “intestinal obstruction/ etiology/ surgery”, “laparoscopy/ adverse effects”, 
“ovarian neoplasms/ epidemiology/ pathology/ surgery”, “ovarian neoplasms/ pathology/ radiography/ 
surgery”, and “splenectomy”. In breast cancer, new MESH in year 2013 were, for example, “bone density 
conservation agents/ adverse effects”, “breast neoplasms, male/ diagnosis”, “breast neoplasms/ 
classification/ pathology/ surgery”, “genital neoplasms, female”, “mastectomy, subcutaneous/ methods”, 




Table 5. Ranking of MESH funded by agencies in 2003 for ovarian cancer. 





































































   
Mice 
(47) 
    
Male 
(44) 
    
Gene Expression Regulation, 
Neoplastic 
(29) 
    
Cell Line, Tumour 
(25) 
    








Table 6. Ranking of MESH funded by agencies in 2013 for ovarian cancer. 
Source: Own source from cleaned PubMed data.  
 
 
Table 7. Ranking of MESH funded by agencies in 2003 for breast cancer. 





















































































































































     


























































































































































     
Risk Factors 
(125) 




     
Time Factors 
(100) 
     
NCI NCRR NIGMS Canadian Inst. 
















































































































    
Male 
(122) 
     
Aged, 80 and 
over 
(117) 
     
Prognosis 
(105) 




In this paper, we have analysed the patterns of co-funded research in two medical topics and 
demonstrated how this pattern varies depending on cross-agencies and cross-national collaboration in 
funding. Moreover, we have studied the relationship between funding agencies and the medical subject 
headings they set out to fund. The paper contributes, in an empirical and exploratory manner, to a 
growing body of knowledge concerning the production of knowledge, and how this knowledge is 
produced and affected by the choices and instruments of funding agencies.  
 
Furthermore, co-funding research analysis gives researchers a thorough insight into the most important 
institutions that support research in a particular topic, and shows the mediator agencies to be contacted 
when it is difficult to achieve a direct link with a funding star --which in our analysis is the NCI. 
Moreover, we can also observe which countries are most directly linked to the United States, and which 
are better positioned, depending on the topic. For example, if we were trying to look for a mediator in 
ovarian cancer, we would find more opportunities in United Kingdom; if the topic were breast cancer, we 
would find our mediator in Canada.  
 
In this paper, we have also detected a trend in agencies to coincide with the MESH they fund. 
Nonetheless, it is difficult to determine whether they fund these headings because of their importance, or 
if they become important because agencies fund them. This is an important area for further research. 
Furthermore, it is readily apparent that agencies, by and large, do not work together.  
 
Analysing a medical bibliography involves difficulties, as we have encountered in our data processing. 
For example, although the PubMed database allowed us to download all the data quickly, cleaning the 
acknowledgement data took a long time. As the data included the project, the funding agencies, as well as 
other information, we had to delete the unnecessary data on a project-by-project basis. Another important 
difficulty was related to limits in working with a large amount of data with VantagePoint and Windows; 
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Annex 1. Cliques in 2013 for ovarian cancer 
 
1. NCI NIH HHS/United States; Canadian Institutes of Health Research/Canada; NICHD NIH HHS/United States; NIGMS NIH 
HHS/United States; NCRR NIH HHS/United States; PHS HHS/United States; NIEHS NIH HHS/United States. 
2. NCI NIH HHS/United States; NICHD NIH HHS/United States; NIGMS NIH HHS/United States; NCRR NIH HHS/United 
States; NCATS NIH HHS/United States; NHLBI NIH HHS/United States. 
3. NCI NIH HHS/United States; NICHD NIH HHS/United States; NIGMS NIH HHS/United States; NCRR NIH HHS/United 
States; NIH HHS/United States. 
4. NCI NIH HHS/United States; Canadian Institutes of Health Research/Canada; Cancer Research UK/United Kingdom; NIGMS 
NIH HHS/United States; NCRR NIH HHS/United States; Medical Research Council/United Kingdom; PHS HHS/United 
States; Wellcome Trust/United Kingdom. 
5. NCI NIH HHS/United States; Canadian Institutes of Health Research/Canada; Cancer Research UK/United Kingdom; NIGMS 
NIH HHS/United States; NCRR NIH HHS/United States; PHS HHS/United States; NIEHS NIH HHS/United States. 
6. NCI NIH HHS/United States; NIGMS NIH HHS/United States; NCRR NIH HHS/United States; NHLBI NIH HHS/United 
States; NIAID NIH HHS/United States. 
7. NCI NIH HHS/United States; NIGMS NIH HHS/United States; NCRR NIH HHS/United States; NHLBI NIH HHS/United 
States; NHGRI NIH HHS/United States. 
8. NCI NIH HHS/United States; NIGMS NIH HHS/United States; NCRR NIH HHS/United States; NHLBI NIH HHS/United 
States; NLM NIH HHS/United States. 
9. NCI NIH HHS/United States; NIGMS NIH HHS/United States; NCATS NIH HHS/United States; NHLBI NIH HHS/United 
States; NIDDK NIH HHS/United States. 
10. NCI NIH HHS/United States; Cancer Research UK/United Kingdom; NIGMS NIH HHS/United States; NIDDK NIH 
HHS/United States. 
11. NCI NIH HHS/United States; NIGMS NIH HHS/United States; NHLBI NIH HHS/United States; Howard Hughes Medical 
Institute/United States. 
12. NCI NIH HHS/United States; NIGMS NIH HHS/United States; NIMHD NIH HHS/United States. 
13. NCI NIH HHS/United States; Cancer Research UK/United Kingdom; Medical Research Council/United Kingdom; 
Department of Health/United Kingdom; Arthritis Research UK/United Kingdom. 
14. NCI NIH HHS/United States; NCRR NIH HHS/United States; NHLBI NIH HHS/United States; NIAID NIH HHS/United 
States; NIBIB NIH HHS/United States. 
15. NCI NIH HHS/United States; NICHD NIH HHS/United States; NCRR NIH HHS/United States; NHLBI NIH HHS/United 
States; NIBIB NIH HHS/United States. 
16. NCI NIH HHS/United States; NICHD NIH HHS/United States; NCRR NIH HHS/United States; NIBIB NIH HHS/United 
States; NIH HHS/United States. 
17. NCI NIH HHS/United States; NHLBI NIH HHS/United States; NIBIB NIH HHS/United States; Howard Hughes Medical 
Institute/United States. 
18. NCI NIH HHS/United States; NIBIB NIH HHS/United States; Howard Hughes Medical Institute/United States; NCCDPHP 
CDC HHS/United States. 
19. NCI NIH HHS/United States; NICHD NIH HHS/United States; NIBIB NIH HHS/United States; NIDCR NIH HHS/United 
States; NIH HHS/United States. 
20. NCI NIH HHS/United States; NICHD NIH HHS/United States; NIEHS NIH HHS/United States; NIA NIH HHS/United 
States. 
21. NCI NIH HHS/United States; NICHD NIH HHS/United States; NCATS NIH HHS/United States; NIA NIH HHS/United 
States. 
22. NCI NIH HHS/United States; NICHD NIH HHS/United States; NIA NIH HHS/United States; NIMH NIH HHS/United States. 
23. NCI NIH HHS/United States; NCATS NIH HHS/United States; NIDDK NIH HHS/United States; NIA NIH HHS/United 
States. 
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24. NCI NIH HHS/United States; NCATS NIH HHS/United States; NIDDK NIH HHS/United States; NIAMS NIH HHS/United 
States. 
25. NCI NIH HHS/United States; NCRR NIH HHS/United States; NCATS NIH HHS/United States; NIAMS NIH HHS/United 
States. 
26. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIAID NIH HHS/United States; NIAMS NIH HHS/United 
States. 
27. NCI NIH HHS/United States; NINDS NIH HHS/United States; NIMH NIH HHS/United States. 
28. NCI NIH HHS/United States; Cancer Research UK/United Kingdom; Medical Research Council/United Kingdom; Wellcome 
Trust/United Kingdom; Chief Scientist Office/United Kingdom. 
29. NCI NIH HHS/United States; NIEHS NIH HHS/United States; NIDA NIH HHS/United States. 
30. NCI NIH HHS/United States; NICHD NIH HHS/United States; NCATS NIH HHS/United States; NIDCR NIH HHS/United 
States. 
31. NCI NIH HHS/United States; Wellcome Trust/United Kingdom; NIDCR NIH HHS/United States; WETP NIH HHS/United 
States. 
32. NCI NIH HHS/United States; NHGRI NIH HHS/United States; NIMH NIH HHS/United States. 
33. NCI NIH HHS/United States; Cancer Research UK/United Kingdom; Medical Research Council/United Kingdom; Wellcome 
Trust/United Kingdom; Arthritis Research UK/United Kingdom. 
34. NCI NIH HHS/United States; NHLBI NIH HHS/United States; NHGRI NIH HHS/United States; WHI NIH HHS/United 
States. 
35. NCI NIH HHS/United States; Cancer Research UK/United Kingdom; NCRR NIH HHS/United States; NIEHS NIH 
HHS/United States; CCR NIH HHS/United States. 
36. Canadian Institutes of Health Research/Canada; NICHD NIH HHS/United States; NIGMS NIH HHS/United States; NCRR 
NIH HHS/United States; NIEHS NIH HHS/United States; British Heart Foundation/United Kingdom. 
37. Canadian Institutes of Health Research/Canada; NIGMS NIH HHS/United States; NCRR NIH HHS/United States; Wellcome 
Trust/United Kingdom; British Heart Foundation/United Kingdom. 
38. NICHD NIH HHS/United States; NIA NIH HHS/United States; NINR NIH HHS/United States. 
 
Annex 2. Cliques in 2013 for breast cancer 
1. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; PHS HHS/United States; 
NIDDK NIH HHS/United States; NHLBI NIH HHS/United States; NCATS NIH HHS/United States; NIA NIH HHS/United 
States; NICHD NIH HHS/United States; NIMHD NIH HHS/United States. 
2. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; PHS HHS/United States; 
NIDDK NIH HHS/United States; NHLBI NIH HHS/United States; NCATS NIH HHS/United States; NIA NIH HHS/United 
States; NICHD NIH HHS/United States; NIDCR NIH HHS/United States. 
3. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; PHS HHS/United States; 
NIDDK NIH HHS/United States; NHLBI NIH HHS/United States; NIEHS NIH HHS/United States; NCATS NIH 
HHS/United States; NIBIB NIH HHS/United States; NICHD NIH HHS/United States. 
4. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; PHS HHS/United States; 
NIDDK NIH HHS/United States; NHLBI NIH HHS/United States; NIEHS NIH HHS/United States; NICHD NIH 
HHS/United States; NHGRI NIH HHS/United States. 
5. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; PHS HHS/United States; 
NIDDK NIH HHS/United States; NHLBI NIH HHS/United States; NIEHS NIH HHS/United States; NIBIB NIH HHS/United 
States; NICHD NIH HHS/United States; NINDS NIH HHS/United States. 
6. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; PHS HHS/United States; 
NIDDK NIH HHS/United States; NHLBI NIH HHS/United States; NIA NIH HHS/United States; NICHD NIH HHS/United 
States; NIDCR NIH HHS/United States; NINDS NIH HHS/United States. 
7. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; PHS HHS/United States; 
NIDDK NIH HHS/United States; NHLBI NIH HHS/United States; NHGRI NIH HHS/United States; NIAID NIH 
HHS/United States; Howard Hughes Medical Institute/United States. 
8. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; PHS HHS/United States; 
NIDDK NIH HHS/United States; NHLBI NIH HHS/United States; NIA NIH HHS/United States; NIAID NIH HHS/United 
States. 
9. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; PHS HHS/United States; 
NIDDK NIH HHS/United States; NHLBI NIH HHS/United States; NCATS NIH HHS/United States; NIBIB NIH 
HHS/United States; Howard Hughes Medical Institute/United States. 
10. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; PHS HHS/United States; 
NIDDK NIH HHS/United States; NHLBI NIH HHS/United States; NIBIB NIH HHS/United States; NINDS NIH HHS/United 
States; Howard Hughes Medical Institute/United States. 
11. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; Canadian Institutes of Health 
Research/Canada; PHS HHS/United States; NIDDK NIH HHS/United States; NIA NIH HHS/United States; NIAID NIH 
HHS/United States. 
12. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; Canadian Institutes of Health 
Research/Canada; PHS HHS/United States; NIDDK NIH HHS/United States; NIA NIH HHS/United States; NIDCR NIH 
HHS/United States. 
13. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; Canadian Institutes of Health 
Research/Canada; PHS HHS/United States; NIDDK NIH HHS/United States; NIA NIH HHS/United States; NCCAM NIH 
HHS/United States. 
14. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; Canadian Institutes of Health 
Research/Canada; PHS HHS/United States; NIDDK NIH HHS/United States; NIEHS NIH HHS/United States; NHGRI NIH 
HHS/United States. 
15. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; Canadian Institutes of Health 
Research/Canada; PHS HHS/United States; NIDDK NIH HHS/United States; NIEHS NIH HHS/United States; NCCAM NIH 
HHS/United States. 
 24 
16. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; Canadian Institutes of Health 
Research/Canada; PHS HHS/United States; NIDDK NIH HHS/United States; NHGRI NIH HHS/United States; NIAID NIH 
HHS/United States. 
17. NCI NIH HHS/United States; NCRR NIH HHS/United States; PHS HHS/United States; NIDDK NIH HHS/United States; 
NHLBI NIH HHS/United States; NIBIB NIH HHS/United States; NINDS NIH HHS/United States; NIAMS NIH HHS/United 
States; Howard Hughes Medical Institute/United States. 
18. NCI NIH HHS/United States; NCRR NIH HHS/United States; PHS HHS/United States; NIDDK NIH HHS/United States; 
NHLBI NIH HHS/United States; NIA NIH HHS/United States; NINDS NIH HHS/United States; NIAMS NIH HHS/United 
States. 
19. NCI NIH HHS/United States; NCRR NIH HHS/United States; PHS HHS/United States; NIDDK NIH HHS/United States; 
NHLBI NIH HHS/United States; NIAMS NIH HHS/United States; AHRQ HHS/United States. 
20. NCI NIH HHS/United States; NCRR NIH HHS/United States; PHS HHS/United States; NIDDK NIH HHS/United States; 
NHLBI NIH HHS/United States; NCATS NIH HHS/United States; NICHD NIH HHS/United States; NIMHD NIH 
HHS/United States; AHRQ HHS/United States. 
21. NCI NIH HHS/United States; NCRR NIH HHS/United States; PHS HHS/United States; NIDDK NIH HHS/United States; 
NHLBI NIH HHS/United States; NICHD NIH HHS/United States; NHGRI NIH HHS/United States; AHRQ HHS/United 
States. 
22. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; Canadian Institutes of Health 
Research/Canada; PHS HHS/United States; Cancer Research UK/United Kingdom; NIEHS NIH HHS/United States. 
23. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; Canadian Institutes of Health 
Research/Canada; PHS HHS/United States; Cancer Research UK/United Kingdom; NIA NIH HHS/United States. 
24. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; PHS HHS/United States; 
Cancer Research UK/United Kingdom; Howard Hughes Medical Institute/United States. 
25. NCI NIH HHS/United States; NCRR NIH HHS/United States; PHS HHS/United States; Cancer Research UK/United 
Kingdom; NIEHS NIH HHS/United States; CCR NIH HHS/United States. 
26. NCI NIH HHS/United States; NCRR NIH HHS/United States; PHS HHS/United States; NCATS NIH HHS/United States; 
NIA NIH HHS/United States; NICHD NIH HHS/United States; NINR NIH HHS/United States. 
27. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; NHLBI NIH HHS/United 
States; NIEHS NIH HHS/United States; NIBIB NIH HHS/United States; NIH HHS/United States; NIDA NIH HHS/United 
States. 
28. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; NHLBI NIH HHS/United 
States; NIEHS NIH HHS/United States; NHGRI NIH HHS/United States; NIH HHS/United States. 
29. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; NHLBI NIH HHS/United 
States; NHGRI NIH HHS/United States; NIAID NIH HHS/United States; Howard Hughes Medical Institute/United States; 
NIH HHS/United States. 
30. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; NHLBI NIH HHS/United 
States; NIAID NIH HHS/United States; NIH HHS/United States; NIDA NIH HHS/United States. 
31. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; NHLBI NIH HHS/United 
States; NIBIB NIH HHS/United States; Howard Hughes Medical Institute/United States; NIH HHS/United States. 
32. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; NIEHS NIH HHS/United 
States; NIH HHS/United States; NCCAM NIH HHS/United States. 
33. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIDDK NIH HHS/United States; NHLBI NIH HHS/United 
States; NIEHS NIH HHS/United States; NHGRI NIH HHS/United States; NIAAA NIH HHS/United States. 
34. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; NHLBI NIH HHS/United 
States; NIEHS NIH HHS/United States; NIBIB NIH HHS/United States; NICHD NIH HHS/United States; NINDS NIH 
HHS/United States; NIDA NIH HHS/United States. 
35. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; NHLBI NIH HHS/United 
States; NIA NIH HHS/United States; NICHD NIH HHS/United States; NINDS NIH HHS/United States; NIDA NIH 
HHS/United States. 
36. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; NHLBI NIH HHS/United 
States; NIA NIH HHS/United States; NICHD NIH HHS/United States; NIMHD NIH HHS/United States; NIDA NIH 
HHS/United States. 
37. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; NHLBI NIH HHS/United 
States; NIA NIH HHS/United States; NIAID NIH HHS/United States; NIDA NIH HHS/United States. 
38. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; Canadian Institutes of Health 
Research/Canada; NIA NIH HHS/United States; NIAID NIH HHS/United States; NIDA NIH HHS/United States. 
39. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; Canadian Institutes of Health 
Research/Canada; NIEHS NIH HHS/United States; NIDA NIH HHS/United States. 
40. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIEHS NIH HHS/United States; NIDA NIH HHS/United 
States; RMOD NIH HHS/United States. 
41. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; NIAID NIH HHS/United 
States; FIC NIH HHS/United States. 
42. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIGMS NIH HHS/United States; NICHD NIH HHS/United 
States; FIC NIH HHS/United States. 
43. NCI NIH HHS/United States; NCRR NIH HHS/United States; NIDDK NIH HHS/United States; NHLBI NIH HHS/United 
States; NCATS NIH HHS/United States; NIBIB NIH HHS/United States; NEI NIH HHS/United States. 
44. NCI NIH HHS/United States; NIGMS NIH HHS/United States; Canadian Institutes of Health Research/Canada; PHS 
HHS/United States; Cancer Research UK/United Kingdom; NIA NIH HHS/United States; Medical Research Council/United 
Kingdom. 
45. NCI NIH HHS/United States; NIGMS NIH HHS/United States; Canadian Institutes of Health Research/Canada; Cancer 
Research UK/United Kingdom; NIA NIH HHS/United States; Medical Research Council/United Kingdom; NIMH NIH 
HHS/United States. 
46. NCI NIH HHS/United States; NIGMS NIH HHS/United States; PHS HHS/United States; Cancer Research UK/United 
Kingdom; Medical Research Council/United Kingdom; Department of Health/United Kingdom. 
47. NCI NIH HHS/United States; NIGMS NIH HHS/United States; Cancer Research UK/United Kingdom; Medical Research 
Council/United Kingdom; NIMH NIH HHS/United States; Department of Health/United Kingdom. 
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48. NCI NIH HHS/United States; Cancer Research UK/United Kingdom; Medical Research Council/United Kingdom; NIMH 
NIH HHS/United States; Department of Health/United Kingdom; British Heart Foundation/United Kingdom. 
49. NCI NIH HHS/United States; Cancer Research UK/United Kingdom; Medical Research Council/United Kingdom; 
Department of Health/United Kingdom; Arthritis Research UK/United Kingdom. 
50. NCI NIH HHS/United States; NIGMS NIH HHS/United States; NCATS NIH HHS/United States; NIA NIH HHS/United 
States; NICHD NIH HHS/United States; NIMH NIH HHS/United States; NIMHD NIH HHS/United States. 
51. NCI NIH HHS/United States; NIGMS NIH HHS/United States; NIA NIH HHS/United States; NICHD NIH HHS/United 
States; NIMH NIH HHS/United States; NIMHD NIH HHS/United States; NIDA NIH HHS/United States. 
52. NCI NIH HHS/United States; NIGMS NIH HHS/United States; NIA NIH HHS/United States; NICHD NIH HHS/United 
States; NIMH NIH HHS/United States; NINDS NIH HHS/United States; NIDA NIH HHS/United States. 
53. NCI NIH HHS/United States; NIGMS NIH HHS/United States; Canadian Institutes of Health Research/Canada; NIA NIH 
HHS/United States; NIMH NIH HHS/United States; NIDA NIH HHS/United States. 
54. NCI NIH HHS/United States; NIGMS NIH HHS/United States; NIBIB NIH HHS/United States; NICHD NIH HHS/United 
States; NIMH NIH HHS/United States; NINDS NIH HHS/United States; NIDA NIH HHS/United States. 
55. NCI NIH HHS/United States; NIGMS NIH HHS/United States; NCATS NIH HHS/United States; NIBIB NIH HHS/United 
States; NICHD NIH HHS/United States; NIMH NIH HHS/United States. 
56. NCI NIH HHS/United States; NIGMS NIH HHS/United States; NICHD NIH HHS/United States; NIMH NIH HHS/United 
States; NHGRI NIH HHS/United States. 
57. NCI NIH HHS/United States; NIGMS NIH HHS/United States; Canadian Institutes of Health Research/Canada; NIMH NIH 
HHS/United States; NHGRI NIH HHS/United States. 
58. NCI NIH HHS/United States; NIMH NIH HHS/United States; Austrian Science Fund FWF/Austria. 
59. NCI NIH HHS/United States; PHS HHS/United States; NIDDK NIH HHS/United States; NHLBI NIH HHS/United States; 
NIA NIH HHS/United States; NICHD NIH HHS/United States; NCCDPHP CDC HHS/United States. 
60. NCI NIH HHS/United States; PHS HHS/United States; NIA NIH HHS/United States; NICHD NIH HHS/United States; 
NCCDPHP CDC HHS/United States; NINR NIH HHS/United States. 
61. NCI NIH HHS/United States; Canadian Institutes of Health Research/Canada; PHS HHS/United States; NIDDK NIH 
HHS/United States; NIA NIH HHS/United States; NCCDPHP CDC HHS/United States. 
62. NCI NIH HHS/United States; PHS HHS/United States; NIDDK NIH HHS/United States; NHLBI NIH HHS/United States; 
NIEHS NIH HHS/United States; NICHD NIH HHS/United States; NCCDPHP CDC HHS/United States. 
63. NCI NIH HHS/United States; Canadian Institutes of Health Research/Canada; PHS HHS/United States; NIDDK NIH 
HHS/United States; NIEHS NIH HHS/United States; NCCDPHP CDC HHS/United States. 
64. NCI NIH HHS/United States; NCCDPHP CDC HHS/United States; ODCDC CDC HHS/United States. 
65. NCI NIH HHS/United States; PHS HHS/United States; NHLBI NIH HHS/United States; NIEHS NIH HHS/United States; 
NICHD NIH HHS/United States; NHGRI NIH HHS/United States; WHI NIH HHS/United States. 
66. NCI NIH HHS/United States; PHS HHS/United States; NHLBI NIH HHS/United States; NIAMS NIH HHS/United States; 
WHI NIH HHS/United States. 
67. NCI NIH HHS/United States; PHS HHS/United States; FDA HHS/United States. 
68. Cancer Research UK/United Kingdom; Medical Research Council/United Kingdom; NIMH NIH HHS/United States; 
Biotechnology and Biological Sciences Research Council/United Kingdom. 
69. Cancer Research UK/United Kingdom; Medical Research Council/United Kingdom; Chief Scientist Office/United 
Kingdom. 
70. NIMH NIH HHS/United States; Department of Health/United Kingdom; European Research Council/International. 
 
 
